GAE is a minimally invasive interventional radiology procedure used to treat symptomatic knee osteoarthritis by selectively reducing abnormal blood flow in the genicular arteries. The procedure provides a non-surgical treatment option for patients who have not responded to conservative management and offers meaningful improvements in pain and mobility.

EmboCept® S, already CE-marked for certain HCC embolisation procedures, it is designed to provide controlled, predictable, and fully degradable vessel occlusion. Extending its use to GAE further strengthens its position as a safe and versatile embolic across multiple therapeutic areas.

The filing submitted today begins the formal assessment under the European Medical Device Regulation (MDR 2017/745). The process involves a review of updated technical documentation and clinical evidence by Magle’s Notified Body to confirm that the expanded intended use is adequately supported. Once approved, GAE will be added as an authorised indication for EmboCept® S across Europe.

“Today’s submission marks a significant step in expanding the impact of EmboCept® S. Genicular Artery Embolisation represents an important therapeutic option for patients with knee osteoarthritis, and our degradable DSM technology is well suited to support physicians performing this procedure. This filing reflects the strength of our evidence generation and our commitment to advancing innovative care for patients,” said Helena Ossmer Thedius, Chief Innovation & Marketing Officer at Magle Group.